Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Central Drug Research Institute (CDRI), a constituent lab of India-based Council of Scientific and Industrial Research (CSIR), has secured approval for carrying out Phase III trial for the use of Umifenovir in the treatment of Covid-19.
In this randomised, double-blind, placebo-controlled trial, CDRI will test the efficacy, safety and tolerability of Umifenovir.
According to a statement by the government: “This drug has a good safety profile and acts by preventing entry of virus into human cells and also by priming the immune system.” Umifenovir is a drug primarily used to treat influenza.